Dyadic International (DYAI) Net Cash Flow Growth (5y) (2023 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Cash Flow Growth (5y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 84.41% |
| Dec 31, 2025 | -1.24% |
| Sep 30, 2025 | -20.58% |
| Jun 30, 2025 | -16.59% |
| Mar 31, 2025 | -63.45% |
| Dec 31, 2024 | 29.76% |
| Sep 30, 2024 | -16.57% |
| Jun 30, 2024 | -49.37% |
| Mar 31, 2024 | 20.50% |
| Dec 31, 2023 | -27.02% |
| Sep 30, 2023 | 24.97% |
| Jun 30, 2023 | 17.63% |
| Mar 31, 2023 | 20.12% |